U.S. Markets open in 2 mins.

OncoGenex Pharmaceuticals, Inc. (OGXI)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.4664+0.0064 (+1.3913%)
At close: 4:00PM EDT
People also watch
THLDRPRXOPXAONTXCYCC

OncoGenex Pharmaceuticals, Inc.

19820 North Creek Parkway
Suite 201
Bothell, WA 98011
United States
425-686-1500
http://www.oncogenex.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees17

Key Executives

NameTitlePayExercisedAge
Mr. Scott Daniel CormackFounder, CEO, Pres, Treasurer, Sec. & Director541.38kN/A52
Mr. John A. Bencich M.B.A.VP & CFO307.5kN/A40
Dr. Cindy Jacobs Ph.D., M.D.Exec. VP & Chief Medical Officer413.23kN/A59
Ms. Jaime WelchVP of Marketing & Corp. CommunicationsN/AN/AN/A
Dr. Patricia S. Stewart M.D.VP of Clinical Devel.N/AN/A75
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The company is headquartered in Bothell, Washington.

Corporate Governance

OncoGenex Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.